European medicines agency confirms acceptance of marketing application for avt03, a proposed biosimilar to prolia® and xgeva®

Reykjavik, iceland, oct. 10, 2024 (globe newswire) -- alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the european medicines agency (ema) has accepted a marketing authorization application for avt03, a proposed biosimilar candidate to prolia® and xgeva® (denosumab).
ALVO Ratings Summary
ALVO Quant Ranking